Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers

References

• Siegel RL, Miller KD, Jemal A; Siegel RL, Miller KD. Cancer statistics, 2019.. CA Cancer J Clin. 2019;69(1):7–14. doi:10.3322/caac.21551.
   PubMed Web of Science ®Google Scholar
• Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis. 2018;12:1–13. doi:10.1177/https.
   Web of Science ®Google Scholar
• Prasad DVR, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500–2506. doi:10.4049/jimmunol.173.4.2500.
   PubMed Web of Science ®Google Scholar
• Chen C, Shen Y, Qu Q, Chen X, Zhang X, Huang J. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res. 2013;319(1):96–102. doi:10.1016/j.yexcr.2012.09.006.
   PubMed Web of Science ®Google Scholar
• Lee YH, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–1045. doi:10.1038/cr.2017.90.
   PubMed Web of Science ®Google Scholar
• Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 2010;116(17):3311–3320. doi:10.1182/blood-2010-02-271981.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non-squamous nonsmall cell lung cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa1507643.Nivolumab.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–1550. doi:10.1016/S0140-6736(15)01281-7.
   PubMed Web of Science ®Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomized controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X.Atezolizumab.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046–2054. doi:10.1200/JCO.2011.38.4032.
   PubMed Web of Science ®Google Scholar
• Sitnik S, Masemann D, Leite Dantas R, Wixler V, Ludwig S. PD-1 IC inhibition synergistically improves influenza a virus-mediated oncolysis of metastatic pulmonary melanoma. Mol Ther - Oncolytics. 2020 17(June;17:190–204. doi:10.1016/j.omto.2020.03.023.
   PubMed Web of Science ®Google Scholar
• Hamilton JR, Vijayakumar G, Palese P. A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model.. Cell Rep. 2018;22(1):1–7. doi:10.1016/j.celrep.2017.12.025.
   PubMed Web of Science ®Google Scholar
• Kellish P, Shabashvili D, Rahman MM, et al. Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival. J Clin Invest. 2019;129(6):2279–2292. doi:10.1172/JCI121323.
   PubMed Web of Science ®Google Scholar
• Durham NM, Mulgrew K, McGlinchey K, et al. Oncolytic VSV primes differential responses toimmuno-oncology therapy. Mol Ther. 2017;25(8):1917–1932. doi:10.1016/j.ymthe.2017.05.006.
   PubMed Web of Science ®Google Scholar
• Bourgeois-Daigneault MC, Roy DG, Aitken AS, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10(422):422. doi:10.1126/scitranslmed.aao1641.
   Web of Science ®Google Scholar
• Sivanandam V, LaRocca CJ, Chen NG, Fong Y, Warner SG. Oncolytic viruses and immune checkpointinhibition: the best of both worlds. Mol Ther - Oncolytics. 2019 June;13:93–106. doi:10.1016/j.omto.2019.04.003.
   PubMed Web of Science ®Google Scholar
• LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1). doi:10.1186/s40169-018-0214-5.
   PubMedGoogle Scholar
• Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, Rapp UR. Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ. 2000;11:185–190.
   PubMedGoogle Scholar
• Masemann D, Köther K, Kuhlencord M, et al. Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages. Oncoimmunology. 2018;7(5):e1423171. doi:10.1080/2162402X.2017.1423171.
   PubMed Web of Science ®Google Scholar
• Pesce S, Greppi M, Grossi F, et al. PD/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019 JUN;10:1–8. doi:10.3389/fimmu.2019.01242.
   PubMed Web of Science ®Google Scholar
• Hsu J, Raulet DH, Ardolino M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade graphical abstract find the latest version : contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J Clin Invest. 2018;128(10):4654–4668. doi:10.1172/JCI99317.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Sampath P, Hou W, Thorne SH. Defining effective combinations of immune checkpointblockade and oncolytic virotherapy. Clin Cancer Res. 2015;21(24):5543–5551. doi:10.1038/nbt.3121.ChIP-nexus.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Haratani K, Takamura S, et al. B7-H3 negatively modulates ctl-mediated cancerImmunity. Clin Cancer Res. 2018;24(11):2653–2664. doi:10.1158/1078-0432.CCR-17-2852.
   PubMed Web of Science ®Google Scholar
• Song J, Shi W, Zhang Y, Sun M, Liang X, Zheng S. Epidermal growth factor receptor and B7-H3 expression in esophageal squamous tissues correlate to patient prognosis. Onco Targets Ther. 2016;9:6257–6263. doi:10.2147/OTT.S111691.
   PubMed Web of Science ®Google Scholar
• Gainor JF, Shaw AT, L V S, et al. EGFR mutations and alk rearrangements are associated with low response rates to pd-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593. doi:10.1158/1078-0432.CCR-153101.EGFR.
   PubMed Web of Science ®Google Scholar
• Xia L, Liu Y, Wang Y. PD‐1/PD‐L1 blockade therapy in advanced non‐small‐cell lung cancer: current status and future directions. Oncologist. 2019;24(S1). doi:10.1634/theoncologist.2019-io-s1s05.
   PubMedGoogle Scholar
• Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170(6):1109–1119.e10. doi:10.1016/j.cell.2017.08.027.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128(4):1413–1428. doi:10.1172/JCI98047.
   PubMed Web of Science ®Google Scholar
• Trefny MP, Kaiser M, Stanczak MA, et al. PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunol Immunother. 2020. doi:10.1007/s00262-020-02558-z.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, et al. A transcriptionally and functionally distinct pd-1 + cd8 + t cell pool with predictive potential in non-small-cell lung cancer treated with pd-1 blockade. Nat Med. 2018;24(7). doi:10.1038/s41591-018-0057-z
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422. doi:10.1158/00085472.CAN-10-4179.
   PubMed Web of Science ®Google Scholar
• Altan M, Pelekanou V, Schalper KA, et al. B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Clin Cancer Res. 2017;22(1):5202–5209. doi:10.1158/10780432.CCR-16-3107.
   Web of Science ®Google Scholar
• Seo JS, Kim A, Shin JY, Kim YT. Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor. Sci Rep. 2018;8(1):1–14. doi:10.1038/s41598-018-32855-8.
   PubMed Web of Science ®Google Scholar
• Sumitomo R, Hirai T, Fujita M, Murakami H, Otake Y. Huang C long. PD-L1 expression on tumorinfiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer. 2019 June;136:136–144. doi:10.1016/j.lungcan.2019.08.023.
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Akiba H, Iwai H, et al. Expression of programmed death 1 ligands by murine T cells andAPC. J Immunol. 2002;169(10):5538–5545. doi:10.4049/jimmunol.169.10.5538.
   PubMed Web of Science ®Google Scholar
• Arlauckas SP, Garris CS, Kohler RH, et al. mediated resistance pathway in anti-PD-1 therapy. Sci TranslMed. 2017;9(389):1–20. doi:10.1126/scitranslmed.aal3604.In.
   Web of Science ®Google Scholar
• Brigati C, Noonan DM, Albini A, Benelli R. Tumors and inflammatory infiltrates: friends or foes? ClinExp Metastasis. 2002;19(3):247–258. doi:10.1023/A:1015587423262.
   PubMed Web of Science ®Google Scholar
• Muster T, Rajtarova J, Sachet M, et al. Interferon resistance promotes oncolysis by influenza virus NS1deletion mutants. Int J Cancer. 2004;110(1):15–21. doi:10.1002/ijc.20078.
   PubMed Web of Science ®Google Scholar
• Bergmann M, Garcia-Sastre A, Carnero E, et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol. 2000;74(13):6203–6206. doi:10.1128/JVI.74.13.6203-6206.2000.
   PubMed Web of Science ®Google Scholar
• Van Rikxoort M, Michaelis M, Wolschek M, et al. Oncolytic effects of a novel influenza a virus expressing interleukin-15 from the NS reading frame. PLoS One. 2012;7(5):e36506. doi:10.1371/journal.pone.0036506.
   PubMed Web of Science ®Google Scholar
• Vigdorovich V, Ramagopal UA, Lázár-molnár E, et al. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 2013;21(5):707–717. doi:10.1016/j.str.2013.03.003.
   Google Scholar
• Mao Y, Chen L, Wang F, et al. Cancer cell‑expressed B7‑H3 regulates the differentiation of tumor‑associated macrophages in human colorectal carcinoma. Oncol Lett. 2017;24(S1):6177–6183. doi:10.3892/ol.2017.6935.
   Google Scholar
• Zhang G, Wang J, Kelly J, et al. B7-H3 augments the inflammatory response and is associated withhuman sepsis. J Immunol. 2010;185(6):3677–3684. doi:10.4049/jimmunol.0904020.
   PubMed Web of Science ®Google Scholar
• Seyer R, Hrincius ER, Ritzel D, et al. Synergistic adaptive mutations in the hemagglutinin and polymerase acidic protein lead to increased virulence of pandemic 2009 H1N1 influenza a virus in mice. J Infect Dis. 2012;205:262–271. doi:10.1093/infdis/jir716.
   PubMed Web of Science ®Google Scholar
• Börgeling Y, Schmolke M, Viemann D, Nordhoff C, Roth J, Ludwig S. Inhibition of p38 mitogenactivated protein kinase impairs influenza virus-induced primary and secondary host gene responses and protects mice from lethal H5N1 infection. J Biol Chem. 2014;289(1):13–27. doi:10.1074/jbc.M113.469239.
   PubMed Web of Science ®Google Scholar